Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

People with chronic obstructive pulmonary disease (COPD) often need to use many different inhalers every day to help them breathe better. But now, there are newer inhalers that combine different ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

“Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data from more recent years are ...

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...